MMMichael P. Mannino

Michael P. Mannino

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michael P. Mannino has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Lead Optimization of TgCDPK1 Inhibitors for the Treatment of Toxoplasmosis

    by Michael P. Mannino, Anusha Gokanapalle, Shrushti Patil, Anoopjit Singh Kooner, Chhuttan Lal Meena, Matthew Medcalf, Igi Vilza, Jennifer Barks, Yong Fu, Jing Xia, et al.

    Toxoplasma gondii is an important opportunistic pathogen that infects many individuals and threatens the health of those with compromised immunity. Current therapies are unable to eradicate chronic infections and pose risks of adverse reactions. Using X-ray structure-based drug design, we have developed a new series of biaryl-substituted pyrazolopyrimidine inhibitors of the essential parasite enzyme calcium-dependent protein kinase 1 (TgCDPK1). These inhibitors have excellent potency against the enzyme and in vitro antiparasitic activity. We further optimized the compounds for increased metabolic stability, lowered plasma protein binding, decreased efflux, and improved pharmacokinetics (PK). Several of the inhibitors had desirable PK with high oral bioavailability, low clearance, and extended half-life, leading to excellent compound exposure in the plasma and brain over a 24-h period. Three compounds were tested during acute infection in both immunocompetent and immunocompromised mice. We identified 16c as a promising preclinical candidate to treat toxoplasmosis.


  • Towards broad-spectrum antiviral drugs: inhibition of transmembrane serine proteases

    by Victoria Banas, Michael P. Mannino, James W. Janetka

    Proteases are important for the pathogenesis of many viruses. These proteolytic enzymes cleave one or more amide bonds of viral proteins. This protein processing is required for viral entry and replication. The most widely utilized for this purpose are serine proteases, the majority of which are host cell transmembrane, or membrane associated serine proteases such as matriptase, TMPRSS2, TMPRSS11D, and TMPRSS13. Several host cysteine proteases like members of the Cathepsin family (e.g. Cathepsin L) are also highjacked by viruses to process viral proteins to infect their hosts. To target these proteases as antiviral drugs, many inhibitors, both competitive and covalent, have been developed but none have been advanced to clinical evaluation to date. Herein, we review these proteases, their viral protein substrates, pathogenesis, and their inhibitors.


  • Front Cover: Structure‐Based Drug Design of Novel Heterocyclic Scaffolds as TgCDPK1 Inhibitors (ChemMedChem 18/2025)

    by Anoopjit Singh Kooner, Mariah Norman, Igi Vilza, Michael P. Mannino, Mary Savari Dhason, Jon Helander, Shrushti Patil, L. David Sibley, James W. Janetka

  • Structure‐Based Drug Design of Novel Heterocyclic Scaffolds as TgCDPK1 Inhibitors

    by Anoopjit Singh Kooner, Mariah Norman, Igi Vilza, Michael P. Mannino, Mary Savari Dhason, Jon Helander, Shrushti Patil, L. David Sibley, James W. Janetka

    Toxoplasmosis is caused by the protozoan parasite Toxoplasma gondii and poses grave health concern for immunocompromised patients. T. gondii has a family of calcium dependent protein kinases (CDPKs) that control a variety of critical processes. Among these, TgCDPK1 is required for parasite motility, cell invasion, and egress and hence is essential both for in vitro growth of T. gondii and to cause infections in animals. Using existing X‐ray cocrystal structures of pyrazolopyrimidine (PP) inhibitors bound to TgCDPK1, six new chemical series of inhibitors are rationally designed. The synthesis of analogs based on the most promising novel series is pursued, which resulted in potent TgCDPK1 inhibitors that effectively block parasite growth in cells. The resulting lead compounds 44 and 45 belonging to the imidazopyrazine chemical series demonstrate the promising potential of this new class of inhibitors for the treatment and possible cure of the Toxoplasmosis.


  • Enantioseparation of α-Hydroxyallylphosphonates and Phosphonoallylic Carbonate Derivatives on Chiral Stationary Phases Using Sequential UV, Polarimetric, and Refractive Index Detection

    by Bruce C. Hamper, Michael P. Mannino, Melissa E. Mueller, Liam T. Harrison, Christopher D. Spilling

    Chromatographic separation of the enantiomers of parent compounds dimethyl α-hydroxyallyl phosphonate 1a and 1-(dimethoxyphosphoryl) allyl methyl carbonate 1b was demonstrated by high-performance liquid chromatography (HPLC) using Chiralpak AS-H and ad-H chiral stationary phases (CSP), respectively, using a combination of UV, polarimetric, and refractive index detectors. A comparison was made of the separation efficiency and elution order of enantiomeric α-hydroxyallyl phosphonates and their carbonate derivatives on commercially available polysaccharide AS, ad, OD, IC-3, and Whelk-O 1 CSPs. In general, the α-hydroxyallyl phosphonates were resolved on the AS-H CSP, whereas the carbonate derivatives 1b and 2b were preferentially resolved on the ad-H CSP. The impact of aryl substitution on the resolution of analytes 1d, 1e, 1f and 2, 3, 4, 5, 6, 7, 8 was evaluated. Thermodynamic parameters determined for enantioselective adsorption hydroxyphosphonates 1a and 4 on the AS-H CSP and carbonate 1b on the ad-H CSP demonstrated enthalpic control for separation of the enantiomers. Chirality 28:656–662, 2016.